Foralumab

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameForalumab
Drug Alias NameNI-0401/α-CD3TZLS-401NI-0401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain inhibitors
TargetsT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Lower Respiratory Tract Infections +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceBrazil
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovimmune SaMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesFhi Clinical IncThe Brigham and Women's HospitalTiziana Life Sciences Ltd +[5] 
Inactive CompaniesLight Chain Bioscience Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionAmyotrophic Lateral Sclerosis +[8] 
Inactive IndicationsRejection of renal transplantationLower Respiratory Tract InfectionsDiabetes Mellitus, Type 2 +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia